[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Liaoning Cancer Hospital & Institute\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":257},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,46,72,94,113,129,149,170,194,214,234],{"id":9,"slug":4,"hasResults":10,"nctId":11,"briefTitle":12,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":10,"sex":15,"minAge":16,"maxAge":17,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":27,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":34,"lastUpdatePostDateStruct":35,"startDateStruct":38,"completionDateStruct":40,"leadSponsor":42,"locationsCount":45},"100641609",false,"NCT07657130","Optimal Application Timing of ADC Drugs for Advanced Breast Cancer","A Prospective, Randomized Controlled Phase II Trial Investigating the Optimal Timing of Antibody Drug Conjugates in Advanced HER2-Negative Breast Cancer Patients","Inclusion Criteria:\n\n1. Female patients aged 18-75 years;\n2. Histologically confirmed advanced HER2-negative breast cancer, including IHC 2+\u002FISH-, IHC 1+\u002FISH-, and IHC 0\u002FISH- subtypes;\n3. Completed first-line combination chemotherapy for advanced\u002Fmetastatic disease (specific regimen not restricted), with disease progression (PD) evaluated per RECIST criteria (HR-positive patients must have received at least one line of endocrine therapy);\n4. Electrocorticography (ECOG) performance status \\\u003C 2;\n5. Estimated life expectancy ≥ 12 weeks;\n6. Adequate bone marrow function, defined as:\n\n   * ANC ≥ 1.5 × 10⁹\u002FL\n   * Platelets ≥ 90 × 10⁹\u002FL\n   * Hemoglobin ≥ 90 g\u002FL\n7. Adequate hepatic and renal function, defined as:\n\n   * Total bilirubin ≤ 1.5 × upper limit of normal (ULN)\n   * AST or ALT ≤ 2.5 × ULN (≤ 5 × ULN for patients with liver metastases)\n   * Creatinine clearance ≥ 60 mL\u002Fmin\n8. Signed informed consent obtained prior to any study-related procedures or treatments, confirming the patient's willingness to participate and comply with study requirements.\n\nExclusion Criteria:\n\n1. Prior treatment with an ADC after disease recurrence or metastasis;\n2. Pregnant or breastfeeding women;\n3. No evaluable recurrent or metastatic lesions as defined by RECIST 1.1 criteria;\n4. Symptomatic brain parenchymal and\u002For leptomeningeal metastases with symptoms not adequately controlled by treatment;\n5. History of other malignancies within the past 5 years, except for adequately treated carcinoma in situ of the cervix, cutaneous squamous cell carcinoma, or well-controlled localized basal cell carcinoma of the skin;\n6. Psychiatric disorders or other conditions that may interfere with patient compliance;\n7. Recent history of serious and uncontrolled systemic diseases, such as clinically significant cardiovascular disease, pulmonary disease, metabolic disorders, or arterial\u002Fvenous thromboembolic events;\n8. Concurrent use of other investigational drugs, or participation in another clinical trial within 30 days prior to enrollment;\n9. Known or suspected allergy to any study drug or its excipients;\n10. Any other condition that, in the opinion of the investigator, renders the patient unsuitable for participation in this trial.","FEMALE","18 Years","75 Years",{"count":19,"type":20},120,"ESTIMATED","INTERVENTIONAL",[23],"PHASE2","This study plans to initiate a prospective, randomized controlled trial to investigate the optimal timing of antibody drug conjugate (ADC) therapy in the management of advanced Human Epidermal Growth Factor Receptor 2 (HER2)-negative breast cancer.\n\nPrimary Objective:\n\nTo compare the difference in PFS2 (Time from randomization to disease progression after second therapy) between antibody-drug conjugate (ADC) followed by chemotherapy versus chemotherapy followed by ADC in the treatment of advanced HER2-negative breast cancer.\n\nSecondary Objectives:\n\nTo compare overall survival (OS), adverse events, patient-reported outcomes, and cost-effectiveness between the two treatment sequences. Additionally, to identify potential biomarkers predictive of benefit from frontline ADC therapy.",[26],"Breast Cancer Females",[28,29,30,31,32],"Breast cancer","Antibody drug conjugate","Timing of application","Randomized controlled trial","HER2-negative","RECRUITING","2026-06-17",{"date":36,"type":37},"2026-06-18","ACTUAL",{"date":39,"type":37},"2025-07-01",{"date":41,"type":20},"2026-12-30",{"name":43,"class":44},"Liaoning Cancer Hospital & Institute","OTHER",1,{"id":47,"slug":4,"hasResults":10,"nctId":48,"briefTitle":49,"officialTitle":50,"acronym":51,"eligibilityCriteria":52,"healthyVolunteers":10,"sex":53,"minAge":4,"maxAge":4,"enrollmentInfo":54,"targetDuration":4,"studyType":21,"phases":56,"briefSummary":58,"conditions":59,"keywords":61,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":65,"lastUpdatePostDateStruct":66,"startDateStruct":68,"completionDateStruct":69,"leadSponsor":71,"locationsCount":45},"100642236","NCT07651644","Two-component Radiology-guided Autonomous Cascade Engine (TRACE)","Protocol for a Prospective Randomised Crossover Controlled Trial of the Artificial Intelligence-Assisted Decision-Making System for Gastric Cancer T-Staging (TRACE)","TRACE","Inclusion Criteria (Imaging Data)\n\n1. Contrast-enhanced CT (CE-CT) images of gastric cancer patients from the Liaoning Cancer Hospital;\n2. Patients with a definitive postoperative pathological diagnosis of gastric cancer and a clear T-stage classification (T1-T4, including T4a and T4b);\n3. Imaging data must be complete and of sufficient quality to meet diagnostic and analytical requirements, with no significant artefacts or missing key data;\n4. Complete clinical and pathological information must be available to establish a diagnostic gold standard for comparison.\n\nPhysician Inclusion Criteria (Image Readers)\n\n1. Radiologists holding a valid medical licence;\n2. From the radiology department of a Grade A tertiary hospital or a non-Grade A tertiary hospital;\n3. Classified as senior or junior physicians based on clinical experience;\n4. Voluntarily participating in this study and completing both the non-AI-assisted and AI-assisted image interpretation tasks.\n\nCase Exclusion Criteria\n\n1. Severe missing imaging data or quality failing to meet analysis requirements (e.g., severe motion artefacts);\n2. Lack of clear postoperative pathological T-staging results;\n3. Cases not involving gastric cancer or with incomplete pathological information;\n4. Cases of duplicate enrolment or inconsistent data recording.\n\nPhysician Exclusion Criteria\n\n1. Those unable to complete all image review tasks or demonstrating severe non-compliance;\n2. Those who withdraw during the study period and are unable to provide complete data for both phases of image review;\n3. Those who fail to complete the AI-assisted and non-AI-assisted interpretation processes as specified.\n\nWithdrawal Criteria\n\n1. Physicians who voluntarily withdraw from the study for personal reasons (e.g., time, health or work commitments);\n2. Physicians who fail to complete the required image review tasks or have data missing in excess of the specified threshold;\n3. Cases where critical data errors are identified during subsequent verification or where pathological results cannot be traced; Data found during the study to be non-compliant with ethical or quality control requirements must be excluded.","ALL",{"count":55,"type":20},54,[57],"NA","This study employed a prospective, randomised crossover trial design to evaluate the clinical utility of the TRACE artificial intelligence system for gastric cancer T-staging. A total of 54 radiologists from tertiary and non-tertiary hospitals, including both senior and junior practitioners, were enrolled. The study aimed to investigate whether AI-assisted diagnosis could improve the diagnostic accuracy of gastric cancer T-staging compared with independent interpretation by radiologists.\n\nAll participants were required to interpret 60 contrast-enhanced CT cases sequentially, completing two readings for each case: one without AI assistance and one with AI assistance; The order of the two readings was randomised, and a one-month washout period was observed between readings to eliminate memory bias. All cases were pathologically confirmed gastric cancer cases (stages T1-T4b), and the study simultaneously recorded the physicians' T-staging diagnostic results and the time taken per case. The 60 cases per radiologist were randomly selected from a pool of 1,000 histologically confirmed gastric cancer cases, stratified by pathological T stage T1-T4b. The reference standard was postoperative pathological T stage. The primary outcome was the change in T-staging accuracy between AI-assisted reading and standard (unaided) reading.The term \"prospective\" in this study refers to the prospective execution of radiologist enrollment, randomization, reading procedures, and data collection.",[60],"Gastric Cancer (Diagnosis)",[62,63,64],"AI","Gastric Cancer","T Stage","2026-06-11",{"date":67,"type":37},"2026-06-16",{"date":36,"type":20},{"date":70,"type":20},"2026-08-07",{"name":43,"class":44},{"id":73,"slug":4,"hasResults":10,"nctId":74,"briefTitle":75,"officialTitle":76,"acronym":4,"eligibilityCriteria":77,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":78,"targetDuration":4,"studyType":21,"phases":80,"briefSummary":82,"conditions":83,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":86,"lastUpdatePostDateStruct":87,"startDateStruct":89,"completionDateStruct":91,"leadSponsor":93,"locationsCount":4},"100605356","NCT07161453","Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Different Postoperative Adjuvant Regimens in Patients With Resectable Adenocarcinoma of the Esophagogastric Junction Who Underwent Radical Surgery After Neoadjuvant Chemotherapy Combined With Immunotherapy and Achieved pCR in Postoperative Pathology","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender not restricted;\n2. Subjects diagnosed with gastric cancer (GC) or gastroesophageal junction cancer (GEJC) through imaging and other examinations, and with histopathological diagnosis of adenocarcinoma;\n3. HER2 overexpression or amplification results are negative;\n4. Subjects who have received neoadjuvant chemotherapy for GC\u002FGEJC before, and have undergone at least 3-4 cycles;\n5. Having undergone radical surgical treatment and with postoperative pathological result reaching pCR\n6. After radical surgery treatment, the investigator assesses that further adjuvant treatment is necessary, and the adjuvant treatment plan must be the one specified in this protocol.\n\nExclusion Criteria:\n\n* 1\\) Gastric cancer that is known to be squamous cell carcinoma, undifferentiated carcinoma, or of other tissue types, or gastric cancer that is adenocarcinoma mixed with other tissue types; 2) Within 3 months before adjuvant therapy, there was a significant clinically significant bleeding symptom or a clear bleeding tendency; 3) Within 6 months before adjuvant therapy, had suffered from intestinal obstruction and\u002For had clinical signs or symptoms of digestive tract obstruction, including incomplete obstruction related to the original disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding; 4) Within 5 years before starting adjuvant therapy, was diagnosed with a malignant tumor (excluding malignant tumors with low metastasis and mortality risks, such as: skin basal cell carcinoma or cervical carcinoma in situ that has been adequately treated); 5) Within 30 days before starting adjuvant therapy, had participated in other clinical studies and used study drugs containing active ingredients;",{"count":79,"type":20},500,[81],"PHASE4","This study is to evaluate the efficacy and safety of different postoperative adjuvant regimens in patients with resectable adenocarcinoma of the esophagogastric junction who underwent radical surgery after neoadjuvant chemotherapy combined with immunotherapy and achieved pCR in postoperative pathology",[84],"Gastric \u002F Gastroesophageal Junction Adenocarcinoma","NOT_YET_RECRUITING","2025-08-30",{"date":88,"type":37},"2025-09-08",{"date":90,"type":20},"2025-09-30",{"date":92,"type":20},"2027-12-31",{"name":43,"class":44},{"id":95,"slug":4,"hasResults":10,"nctId":96,"briefTitle":97,"officialTitle":98,"acronym":4,"eligibilityCriteria":99,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":100,"targetDuration":4,"studyType":21,"phases":102,"briefSummary":103,"conditions":104,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":105,"lastUpdatePostDateStruct":106,"startDateStruct":108,"completionDateStruct":110,"leadSponsor":112,"locationsCount":4},"100604412","NCT07149181","Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer\u002FAdenocarcinoma of the Esophagogastric Junction After Radical Surgery","A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as Postoperative Adjuvant Regimens in Patients With Resectable Gastric Cancer\u002FAdenocarcinoma of the Esophagogastric Junction After Radical Surgery","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender not restricted;\n2. Subjects diagnosed with gastric cancer (GC) or gastroesophageal junction cancer (GEJC) through imaging and other examinations, and with histopathological diagnosis of adenocarcinoma;\n3. HER2 overexpression or amplification results are negative;\n4. After radical surgery treatment, the investigator assesses that further adjuvant treatment is necessary, and the adjuvant treatment plan must be the one specified in this protocol.\n\nExclusion Criteria:\n\n1. Gastric cancer that is known to be squamous cell carcinoma, undifferentiated carcinoma, or of other tissue types, or gastric cancer that is adenocarcinoma mixed with other tissue types;\n2. Within 3 months before adjuvant therapy, there was a significant clinically significant bleeding symptom or a clear bleeding tendency;\n3. Within 6 months before adjuvant therapy, had suffered from intestinal obstruction and\u002For had clinical signs or symptoms of digestive tract obstruction, including incomplete obstruction related to the original disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding;\n4. Within 5 years before starting adjuvant therapy, was diagnosed with a malignant tumor (excluding malignant tumors with low metastasis and mortality risks, such as: skin basal cell carcinoma or cervical carcinoma in situ that has been adequately treated);\n5. Within 30 days before starting adjuvant therapy, had participated in other clinical studies and used study drugs containing active ingredients;",{"count":101,"type":20},1000,[81],"This study is to evaluate the efficacy and safety of chemotherapy combined with or without immunotherapy as postoperative adjuvant regimens in patients with resectable gastric cancer\u002Fadenocarcinoma of the esophagogastric junction after radical surgery",[84],"2025-08-23",{"date":107,"type":37},"2025-08-29",{"date":109,"type":20},"2025-08-31",{"date":111,"type":20},"2028-09-30",{"name":43,"class":44},{"id":114,"slug":4,"hasResults":10,"nctId":115,"briefTitle":116,"officialTitle":117,"acronym":4,"eligibilityCriteria":118,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":119,"targetDuration":4,"studyType":21,"phases":120,"briefSummary":121,"conditions":122,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":123,"lastUpdatePostDateStruct":124,"startDateStruct":126,"completionDateStruct":127,"leadSponsor":128,"locationsCount":4},"100603131","NCT07132528","Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","A Multicenter, Prospective, Real-world Study Comparing the Efficacy and Safety of Chemotherapy Combined With or Without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer","Inclusion Criteria:\n\n1. Age ≥ 18 years old, gender not restricted;\n2. Subjects diagnosed with gastric cancer (GC) or gastroesophageal junction cancer (GEJC) through imaging and other examinations, and with histopathological diagnosis of adenocarcinoma;\n3. HER2 overexpression or amplification results are negative;\n4. Subjects who have received neoadjuvant chemotherapy for GC\u002FGEJC before, and have undergone at least 3-4 cycles;\n5. After radical surgery treatment, the investigator assesses that further adjuvant treatment is necessary, and the adjuvant treatment plan must be the one specified in this protocol.\n\nExclusion Criteria:\n\n1. Gastric cancer that is known to be squamous cell carcinoma, undifferentiated carcinoma, or of other tissue types, or gastric cancer that is adenocarcinoma mixed with other tissue types;\n2. Within 3 months before adjuvant therapy, there was a significant clinically significant bleeding symptom or a clear bleeding tendency;\n3. Within 6 months before adjuvant therapy, had suffered from intestinal obstruction and\u002For had clinical signs or symptoms of digestive tract obstruction, including incomplete obstruction related to the original disease or requiring routine parenteral hydration, parenteral nutrition, or tube feeding;\n4. Within 5 years before starting adjuvant therapy, was diagnosed with a malignant tumor (excluding malignant tumors with low metastasis and mortality risks, such as: skin basal cell carcinoma or cervical carcinoma in situ that has been adequately treated);\n5. Within 30 days before starting adjuvant therapy, had participated in other clinical studies and used study drugs containing active ingredients;",{"count":101,"type":20},[81],"This study is to evaluate the efficacy and safety of chemotherapy combined with or without Immunotherapy as an Adjuvant Treatment After Radical Surgery for Patients With Resectable Adenocarcinoma of the Esophagogastric Junction of Gastric Cancer",[84],"2025-08-17",{"date":125,"type":37},"2025-08-20",{"date":109,"type":20},{"date":111,"type":20},{"name":43,"class":44},{"id":130,"slug":4,"hasResults":10,"nctId":131,"briefTitle":132,"officialTitle":133,"acronym":4,"eligibilityCriteria":134,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":135,"targetDuration":4,"studyType":21,"phases":137,"briefSummary":138,"conditions":139,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":141,"lastUpdatePostDateStruct":142,"startDateStruct":144,"completionDateStruct":146,"leadSponsor":148,"locationsCount":4},"100585927","NCT06908733","Integrating Surgery and Radiotherapy Following Tislelizumab-based Conversion Therapy in N3-Stage III NSCLC","Prognosis and Patient-Reported Outcomes of Combined Local Treatments (Surgery and Radiotherapy or Radiotherapy Alone) With Tislelizumab and Chemotherapy in Initial Stage III-N3 Non-Small Cell Lung Cancer: A Prospective, Open-Label, Single-Arm, Phase II Trial","Inclusion Criteria:\n\n1. Aged 18 years or older (inclusive);\n2. Willingness to participate and provide written informed consent;\n3. Eastern Cooperative Oncology Group (ECOG) performance status score of 0 or 1, with no deterioration in the two weeks prior to treatment, and an expected survival of at least 12 weeks;\n4. Histologically or cytologically confirmed non-small cell lung cancer (NSCLC), T1-4N3M0 (AJCC 9th edition); suspicious lymph nodes on whole-body 18F-fluorodeoxyglucose positron emission tomography (PET) or contrast-enhanced computed tomography (CT) or PET-CT should undergo invasive lymph node staging which can be confirmed through endobronchial ultrasound, mediastinoscopy, thoracoscopy, or needle biopsy; however, mandatory confirmation is not required for highly suspicious mediastinal lymph nodes in zones 5 and 6;\n5. For patients with non-squamous cell carcinoma, EGFR, ALK, etc., testing results based on tumor tissue or blood samples must be provided; for squamous NSCLC patients, if the sensitive gene mutation status is unknown, it is not required to perform such tests during screening;\n6. No prior systemic therapy or local treatment after diagnosis of NSCLC;\n7. At least one measurable lesion according to RECIST 1.1 criteria at baseline. The longest diameter should be ≥10 mm (if a lymph node, the shortest diameter should be ≥15 mm). The chosen method of measurement should be suitable for accurate repeated measurements, such as CT or MRI. If only one measurable lesion exists, it may be accepted as the target lesion, evaluated at least 14 days after diagnostic biopsy. Baseline imaging assessment should be performed within 28 days before the first dose of study medication;\n8. Women of childbearing potential must use effective contraception from screening until six months after discontinuation of study treatment and should not breastfeed. Prior to starting treatment, a negative pregnancy test is required, or one of the following criteria proving no risk of pregnancy: ① Postmenopausal defined as age greater than 50 years and amenorrhea for at least 12 months following cessation of all exogenous hormonal replacement therapy; ② Women under 50 years old who have been amenorrheic for 12 months or more after stopping all exogenous hormonal therapy and whose levels of luteinizing hormone (LH) and follicle-stimulating hormone (FSH) fall within laboratory postmenopausal reference ranges are also considered postmenopausal; ③ History of irreversible sterilization surgery including hysterectomy, bilateral oophorectomy, or bilateral salpingectomy, but not bilateral tubal ligation;\n9. Non-sterilized males must use barrier contraception (i.e., condoms) from screening until six months after discontinuation of study treatment; sterilized males are defined as: a. Males with azoospermia confirmed by semen sample examination prior to the study, serving as definitive evidence of male sterilization; b. In this study, males known to have \"low sperm count\" (meeting the definition of \"subfertility\") are still considered fertile and not infertile.\n\nExclusion Criteria:\n\n1. Diagnosed with Pancoast tumor;\n2. Pathologically confirmed large cell neuroendocrine carcinoma (LCNEC);\n3. Primary tumor or metastatic lymph nodes infiltrating major vessels\u002Faorta, trachea, esophagus, heart, etc.;\n4. Any of the following prior treatments: ① Previous lung surgery; ② Prior systemic chemotherapy, immunotherapy, targeted therapy, or any other anti-tumor treatment for lung cancer; ③ Known presence of epidermal growth factor receptor (EGFR) mutations, ALK rearrangements, ROS1 rearrangements, BRAF V600 mutations, RET rearrangements, MET exon 14 skipping mutations, NTRK1\u002F2\u002F3 rearrangements, or other sensitive mutations; ④ Prior radiotherapy to the lungs; ⑤ Major surgery within 14 days prior to first dose or within 28 days if not fully recovered from toxicity and\u002For complications; ⑥ Use of traditional Chinese medicine with anti-tumor effects is allowed if discontinued at least 2 weeks before study drug administration and used for no more than 7 days;\n5. Diagnosis of other malignancies within the last 5 years, except for completely resected basal cell or squamous cell skin cancer, superficial bladder cancer, carcinoma in situ of the cervix, or breast carcinoma in situ;\n6. Active autoimmune disease or history of autoimmune disease that may recur \\[excluding patients with well-controlled type 1 diabetes, hypothyroidism (if controlled by hormone replacement therapy alone), celiac disease, non-systemic dermatological conditions (e.g., vitiligo, psoriasis, alopecia), or any other disease not expected to recur without external triggers\\];\n7. Conditions requiring systemic corticosteroid therapy (\\> 10 mg\u002Fday prednisone or equivalent) or other immunosuppressive medications within 14 days prior to first dose \\[patients currently or previously using any of the following steroid regimens are eligible: adrenal replacement steroids (prednisone ≤ 10 mg\u002Fday or equivalent), minimal systemic absorption of local, ocular, intra-articular, intranasal, and inhaled corticosteroids, short-term (≤ 7 days) use of corticosteroids for prophylaxis or treatment of non-autoimmune conditions\\];\n8. Uncontrolled diabetes or laboratory abnormalities (\\> Grade 1) in potassium, sodium, or corrected calcium despite standard medical management within 14 days prior to first dose;\n9. Uncontrolled pleural effusion, pericardial effusion, or ascites requiring frequent drainage (recurrence within 2 weeks after intervention);\n10. History of interstitial lung disease or active interstitial lung disease, pneumonitis (non-infectious), or uncontrolled pulmonary conditions (e.g., pulmonary fibrosis, acute interstitial lung disease);\n11. Fever ≥ 38°C within 7 days prior to first dose, significant active infection, active tuberculosis, or active fungal, bacterial, or viral infections requiring systemic treatment \\[chronic hepatitis B virus (HBV) or hepatitis C virus (HCV) infection patients receiving antiviral therapy are allowed\\];\n12. Untreated chronic hepatitis B or chronic HBV carriers with HBV DNA \\> 500 IU\u002FmL (or \\> 2500 copies\u002FmL) \\[inactive hepatitis B surface antigen (HBsAg) carriers, treated and stable hepatitis B patients (HBV DNA \\\u003C 500 IU\u002FmL or \\\u003C 2500 copies\u002FmL) are eligible. Patients with detectable HBsAg or HBV DNA should be managed according to guidelines\\];\n13. Active HCV infection \\[patients with negative HCV antibody tests or positive HCV antibody but negative HCV RNA tests are eligible. Only patients with positive HCV antibody tests will undergo HCV RNA testing\\];\n14. Known history of HIV infection;\n15. Prior allogeneic stem cell transplantation or organ transplantation;\n16. Any cardiovascular risk factors: ① Cardiac chest pain within 28 days prior to first dose; ② Pulmonary embolism within 28 days prior to first dose; ③ Acute myocardial infarction within 6 months prior to first dose; ④ NYHA Class III or IV heart failure within 6 months prior to first dose; ⑤ ≥ Grade 2 ventricular arrhythmia within 6 months prior to first dose; ⑥ Cerebrovascular accident within 6 months prior to first dose; ⑦ Uncontrolled hypertension (≥ CTCAE Grade 3) despite medication within 28 days prior to first dose; ⑧ Syncope or seizure within 28 days prior to first dose; ⑨ Left ventricular ejection fraction (LVEF) ≤ 40% \\[patients with coronary artery disease, congestive heart failure not meeting the above criteria, or LVEF between 40% and 50% must receive optimized stable treatment as per their physician's advice, consulting a cardiologist if necessary\\];\n17. History of severe hypersensitivity reactions to chimeric or humanized antibodies or fusion proteins;\n18. Allergy to pemetrexed, its excipients, cisplatin\u002Fcarboplatin, albumin-bound paclitaxel, or other platinum compounds; contraindications to cisplatin such as hearing impairment;\n19. Severe or uncontrolled systemic diseases, unstable or uncompensated respiratory, hepatic, or renal diseases;\n20. Insufficient bone marrow reserve or organ function, meeting any of the following laboratory limits (without corrective treatment within one week prior to blood draw): ① Absolute neutrophil count \\\u003C 1.5 × 10\\^9\u002FL; ② Platelet count \\\u003C 90 × 10\\^9\u002FL; ③ Hemoglobin \\\u003C 90 g\u002FL (\\\u003C 9 g\u002FdL); ④ Alanine aminotransferase \\> 2.5 × ULN; ⑤ Aspartate aminotransferase \\> 2.5 × ULN; ⑥ Total bilirubin \\> 1.5 × ULN (Gilbert syndrome allowed); ⑦ Creatinine \\> 1.5 × ULN (confirmation of creatinine clearance required); ⑧ Serum albumin (ALB) \\\u003C 25 g\u002FL; ⑨ INR or aPTT \\> 1.5 × ULN for patients not on anticoagulant therapy;\n21. Any immunotherapy (e.g., interleukins, interferons, thymosin, etc.) or experimental treatment within 14 days or 5 half-lives (whichever is longer) prior to first dose;\n22. Live vaccines or live-attenuated vaccines within 28 days prior to first dose \\[seasonal influenza vaccines are generally inactivated and allowed; intranasal vaccines are live and not allowed\\];\n23. Underlying diseases (including laboratory abnormalities), alcohol or drug abuse, or dependence that could interfere with study treatment administration, toxicity assessment, adverse event interpretation, or reduce compliance with the study protocol;\n24. Concurrent participation in another therapeutic clinical trial \\[concurrent participation in observational or non-interventional studies is allowed\\];\n25. Pregnant, lactating, or planning to become pregnant during the study period;\n26. Participants judged by the investigator to have poor compliance with study procedures and requirements due to a history of neurological or psychiatric disorders (including epilepsy or dementia), current mental health conditions, etc.;\n27. Participants deemed by the investigator to have any condition that endangers safety or interferes with study assessments.",{"count":136,"type":20},30,[23],"This is a prospective, open, multicenter, Phase II single-arm clinical study. In subjects with an initial stage of stage III-N3 non-small cell lung cancer (NSCLC) that was negative for sensitive gene mutations and had not received any systemic or local therapy (T1-4N3M0, excluding primary tumor or metastatic lymph node invasion of the aorta\u002Ftrachea\u002Fesophagus\u002Fheart, etc.); After 3-4 cycles of Tislelizumab combined with platinum-containing dual agents, the patients without disease progression were evaluated by MDT and selected according to the patient's wishes, including those who could receive conventional\u002Fstandard radical lung cancer surgery (excluding total lung resection). Conventional\u002Fstandard resection of primary, ipsilateral hilum and ipsilateral mediastinum combined with hypofractionted chemoradiotherapy of N3 metastatic lymph nodes was performed. For patients who are inoperable or unwilling to undergo surgery or intolerant to surgery, conventional concurrent chemoradiotherapy is given. Maintenance therapy with Tislelizumab was continued after local treatment until disease progression, drug intolerance as assessed by imaging, or after 1 year; Participants were followed up according to the procedure to evaluate efficacy and patient-reported outcomes.\n\nThe study included a screening period (no more than 28 days after subjects signed informed consent to the first dose), a treatment period (including Tislelizumab combined with chemotherapy-restaging and MDT-local treatment-maintenance therapy), and a follow-up period.\n\nThirty patients：30 patients Primary endpoint: 1-year EFS rate Secondary endpoints: EFS, OS, surgical rate, TTDM, TTLR, AEs, PROs Exploratory end points: Imaging efficacy, pathological efficacy and other relevant clinical outcomes; Predictive biomarkers based on tissue and blood samples.",[140],"Non-Small Cell Lung Cancer (Stage III)","2025-04-02",{"date":143,"type":37},"2025-04-03",{"date":145,"type":20},"2025-03-31",{"date":147,"type":20},"2029-12-30",{"name":43,"class":44},{"id":150,"slug":4,"hasResults":10,"nctId":151,"briefTitle":152,"officialTitle":153,"acronym":4,"eligibilityCriteria":154,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":155,"enrollmentInfo":156,"targetDuration":4,"studyType":21,"phases":158,"briefSummary":159,"conditions":160,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":162,"lastUpdatePostDateStruct":163,"startDateStruct":165,"completionDateStruct":167,"leadSponsor":169,"locationsCount":4},"100574820","NCT06764251","Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer\u002Fgastroesophageal Junction Adenocarcinoma","A Single-centre Phase II Clinical Study of Tislelizumab Combined with SOX Regimen in the Treatment of Locally Advanced Gastric Cancer\u002Fgastroesophageal Junction Adenocarcinoma","Inclusion Criteria:\n\n1. Willing to participate in this study, able to sign the informed consent form, and with compliance;\n2. No gender restriction, aged ≥18 and ≤70 years (at the time of signing the informed consent form);\n3. ECO score of 0-1;\n4. Estimated survival ≥6 months;\n5. HER-2 negative;\n6. Central laboratory confirmed PD-L1 expression in the, with a combined positive score (CPS) ≥1;\n7. Histological and radiological assessment confirmed as advanced gastric cancer (GC) or gastroesal junction (GEJ) adenocarcinoma, with a clinical stage of cT3-T4aN M0;\n8. Pre-enrollment by the attending physician to determine eligibility for R0 resection with curative intent;\n9. Good cardiac function. Patients with underlying ischemic, valvular disease, or other severe heart disease should have a preoperative assessment by a cardiologist if there are clinical indications;\n10. No prior cytotoxic or targeted, no prior partial or complete esophagogastric tumor resection;\n11. Negative for hepatitis B surface antigen (HBsAg) and hepatitis core antibody (HBcAb). If HBsAg is positive or HBcAb is positive, then the hepatitis B virus deoxyribonucleic acidHBV-DNA) must be \\\u003C1000 copies\u002FmL or \\\u003C200 IU\u002FmL or \\\u003Cthe upper limit of normal (ULN) at research center to be eligible;\n12. Negative for hepatitis C virus (HCV) antibody;\n13. Normal major organ function, as defined by the criteria (within 14 days before the first dose, without transfusions, albumin, recombinant human thrombopoietin, or colony-stulating factor (CSF) treatment): Blood routine examination: Hemoglobin (Hb) ≥90g\u002FL; absolute neutrophil count (ANC ≥1.5×109\u002FL; platelets (PLT) ≥80×109\u002FL; Biochemical examination: Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) ≤2.5×ULN (≤5×ULN liver metastasis); total bilirubin (TBIL) ≤1.5×ULN (≤3×ULN for Gilbert's syndrome); seruminine (Cr) ≤1.5×ULN, or creatinine clearance rate ≥60mL\u002Fmin; Coagulation function: Activated partialboplastin time (APTT), international normalized ratio (INR), and prothrombin time (PT) ≤1.5×ULN; Dpler ultrasound assessment: Left ventricular ejection fraction (LVEF) ≥50%; Normal thyroid function, defined as thyroid-stimulating hormone (T) within the normal range. If baseline TSH is out of range, patients with total T3 (or FT3) and FT4 within the normal range also be included; Clinical judgment by the doctor that organ function is sufficient.\n14. Fertile subjects must use appropriate contraception during the study and for 20 days after the study ends, have a negative serum pregnancy test within 7 days before enrollment, and must not be breastfeeding\n\nExclusion Criteria:\n\n1. Have had or simultaneously have other active malignant tumors within 5 years. Cured localized tumors, as basal cell carcinoma of the skin, squamous cell carcinoma of the skin, superficial bladder cancer, prostate carcinoma in situ, cervical carcinoma in situ, and breast in situ, are eligible;\n2. Patients who are preparing for or have previously undergone organ or bone marrow transplantation;\n3. Have ≥2 grade myocardial ischem or myocardial infarction, arrhythmia (QTc ≥470ms), and ≥2 grade congestive heart failure (New York Heart AssociationNYHA\\] classification);\n4. Human immunodeficiency virus (HIV) infection;\n5. Have active pulmonary tuberculosis;\n6. Have a history or current presence interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-related pneumonia, severe pulmonary dysfunction, etc., which may interfere with the detection and management of suspected drug-related pulmonary toxicity;\n7. Have known active or suspected autoimmune diseases, except those in a stable state at the time of enrollment (not requiring systemic immunospressive therapy);\n8. Have received live vaccine treatment within 28 days before the first dose; seasonal flu vaccines are not included;\n9. Have received or need receive systemic corticosteroids (\\> 10 mg\u002Fday prednisone equivalent dose) or other immunosuppressive drugs within 14 days before the dose or during the study. However, the following cases are allowed: patients with no active autoimmune diseases can use topical or inhaled corticosteroids, or hormone replacement therapy with a dose ≤ 10 mg\u002Fday prednisone equivalent dose;\n10. Have any active infection that requires systemic anti-infective within 14 days before the first dose; prophylactic antibiotic treatment (e.g., for urinary tract infections or chronic obstructive pulmonary disease) is not;\n11. Have previously received other antibodies\u002Fdrugs targeting immune checkpoints, such as PD-1, PD-L1, CTLA4, etc.;\n12. Are currently receiving other clinical study treatments, or the time between the end of the previous clinical study treatment and the planned start of this study treatment is less than14 days;\n13. Have a known severe allergic history to any monoclonal antibody or excipients of the study drug;\n14. Have a history of psychiatric drug abuse or drug addiction; patients who have stopped drinking alcohol can be enrolled; According to the investigator's judgment, patients with serious concomitant that endanger the safety of the subjects or affect the completion of the study, or patients who are deemed unsuitable for enrollment for other reasons","70 Years",{"count":157,"type":20},20,[23],"This study is to evaluate the efficacy of neoadjuvant long-term treatment with tislelizumab in combination with SOX in the treatment of locally advanced gastric\u002Fgastroesophageal junction adenocarcinoma.",[161],"Gastric\u002FGastroesophageal Junction Adenocarcinoma","2025-01-01",{"date":164,"type":37},"2025-01-08",{"date":166,"type":20},"2024-12-30",{"date":168,"type":20},"2028-03-31",{"name":43,"class":44},{"id":171,"slug":4,"hasResults":10,"nctId":172,"briefTitle":173,"officialTitle":174,"acronym":4,"eligibilityCriteria":175,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":17,"enrollmentInfo":176,"targetDuration":4,"studyType":178,"phases":4,"briefSummary":179,"conditions":180,"keywords":182,"overallStatus":33,"whyStopped":4,"lastUpdateSubmitDate":186,"lastUpdatePostDateStruct":187,"startDateStruct":189,"completionDateStruct":191,"leadSponsor":193,"locationsCount":45},"100524494","NCT06109454","Observation on the Therapeutic Effect of Huaier Granules in the Adjuvant Treatment of Non-small Cell Lung Cancer After Radical Surgery","Observational Study on the Efficacy and Safety of Huaier Granules Compared With Platinum Containing Dual Drug Combination Chemotherapy in Adjuvant Therapy for Resectable Stage II-IIIA Non-small Cell Lung Cancer After Radical Surgery","Inclusion Criteria:\n\n* 18 years old ≤ age ≤ 75, regardless of gender.\n* Confirmed as non-small cell lung cancer by histopathology, with pathological staging of stage Ⅱ-ⅢA.\n* Received radical R0 resection of lung cancer within 2 months before enrollment, and did not receive any postoperative adjuvant therapy or preoperative neoadjuvant therapy.\n* ECOG（Eastern Cooperative Oncology Group）score:0-2.\n* The patient voluntarily participated in the study, agreed to cooperate with the researcher for data collection, and signed an informed consent form.\n\nExclusion Criteria:\n\n* Known to be allergic to the components of Huaier granules or avoid or use Huaier granules with caution (Huaier group).\n* Those who have difficulty swallowing, complete or incomplete gastrointestinal obstruction, active gastrointestinal bleeding, perforation, and other causes of difficulty in taking oral medication.\n* Non-small cell lung cancer patients who plan to receive targeted therapy, immunotherapy, chemotherapy combined with immunotherapy, radiotherapy, synchronous radiotherapy and chemotherapy during the study period.\n* The patient has a history of other new malignant tumors within 5 years.\n* The expected survival time of the patient is less than half a year.\n* Surgical complications that have not recovered or are accompanied by severe infections after radical resection of lung cancer.\n* Pregnant or lactating women or planned pregnancy preparation.\n* The patient has received other traditional Chinese patent medicines and simple preparations with anti-tumor effect in the past one month (including but not limited to compound cantharidin capsule, cinobufagin capsule, Kangai injection, Brucea javanica injection, etc., the specific instructions shall prevail).\n* The patient suffers from severe mental illness or other reasons that the researcher deems unsuitable to participate in this study.",{"count":177,"type":20},240,"OBSERVATIONAL","This study is a multicenter, prospective, and observational clinical study aimed at exploring whether the 3-year DFS in the Huaier group is not inferior to the control group receiving standard platinum dual-drug chemotherapy.",[181],"Non-small Cell Lung Cancer",[183,181,184,185],"Huaier granule","Efficacy","Safety","2024-05-08",{"date":188,"type":37},"2024-05-10",{"date":190,"type":37},"2024-03-21",{"date":192,"type":20},"2028-10",{"name":43,"class":44},{"id":195,"slug":4,"hasResults":10,"nctId":196,"briefTitle":197,"officialTitle":198,"acronym":4,"eligibilityCriteria":199,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":4,"enrollmentInfo":200,"targetDuration":4,"studyType":21,"phases":202,"briefSummary":203,"conditions":204,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":206,"lastUpdatePostDateStruct":207,"startDateStruct":209,"completionDateStruct":211,"leadSponsor":213,"locationsCount":4},"100539094","NCT06299371","Adebrelimab Plus Chemotherapy as Neoadjuvant Therapy in Resectable NSCLC Harboring Driver Gene Mutations","A Prospective, Single-arm Study of Adebrelimab in Combination With Paclitaxel for Injection (Albumin Bound) and Platinum Chemotherapy as Neoadjuvant Therapy in Resectable Non-Small Cell Lung Cancer (NSCLC) Harboring Driver Gene Mutations","Inclusion Criteria:\n\n* Male or female aged ≥18 years.\n* Eastern Cooperative Oncology Group (ECOG) Performance Status of 0-1.\n* Resectable non-small cell lung cancer harboring driver gene mutations.\n* At least one measurable disease based on Response Evaluation Criteria in Solid Tumors 1.1.\n* Have adequate organ function.\n* Female subjects of childbearing potential must have a negative urine or serum pregnancy test within 72 hours prior to receiving the first dose of study medication；Females should not be breastfeeding；Female subjects of childbearing potential as well as males sexually active with women of childbearing potential must be willing to use an adequate method of contraception.\n* Voluntarily comply with the treatment protocol.\n\nExclusion Criteria:\n\n* Previously treated with any anti-tumor therapy;\n* Subject with known autoimmune disease\n* Subject with known history of testing positive for human immunodeficiency virus (HIV) or known to have acquired immunodeficiency syndrome (AIDS), subject has known active hepatitis B or C.\n* Presence of third space effusion that cannot be controlled by drainage or other means (e.g., excessive pleural fluid and ascites).\n* Subject with severe liver and kidney dysfunction.\n* Subjects who need to use corticosteroids (\\>10 mg\u002Fday prednisone or equivalent dose of similar drugs) or other immunosuppressive therapy for systematic treatment within 14 days before the first administration of the study\n* Subject with previous malignancies within 5 years, except for cured in situ cancer.\n* Subject with previous or current pulmonary fibrosis, interstitial pneumonia, pneumoconiosis, radiation pneumonia, drug-induced pneumonia and severe damage to lung function.\n* Subject with uncontrolled hypertension.\n* Prior organ transplantation including allogenic stem-cell transplantation.\n* Known hypersensitivity to the study drug or any of its excipients.\n* Other situations that the investigator considers unsuitable for the enrollment.",{"count":201,"type":20},36,[23],"This is a prospective, single-arm study to investigate the efficacy and safety of Adebrelimab in combination with paclitaxel for injection (albumin bound) and platinum chemotherapy as neoadjuvant therapy in resectable non-small cell lung cancer harboring driver gene mutations",[205],"Non Small Cell Lung Cancer","2024-02-29",{"date":208,"type":37},"2024-03-07",{"date":210,"type":20},"2024-04-15",{"date":212,"type":20},"2029-04-15",{"name":43,"class":44},{"id":215,"slug":4,"hasResults":10,"nctId":216,"briefTitle":217,"officialTitle":217,"acronym":4,"eligibilityCriteria":218,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":219,"enrollmentInfo":220,"targetDuration":4,"studyType":21,"phases":222,"briefSummary":223,"conditions":224,"keywords":4,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":226,"lastUpdatePostDateStruct":227,"startDateStruct":229,"completionDateStruct":231,"leadSponsor":233,"locationsCount":4},"100494621","NCT05720559","Early Blocking Strategy for Metachronous Liver Metastasis of Colorectal Cancer Based on Pre-hepatic CTC Detection","Inclusion Criteria:\n\n1. Ages 18-80 at the time of signing the informed consent;\n2. Histologically or cytologically confirmed adenocarcinoma of the colon or rectum;\n3. Radical surgery has been performed;\n4. Imaging examination showed no liver metastasis;\n5. Prehepatic CTC number ≥1;\n6. The ECOG performance status is 0-1.\n7. No combination of other life-threatening diseases;\n8. Willingness and ability to follow scheduled visits, treatment plans, laboratory tests and other research procedures.\n\nExclusion Criteria:\n\n1. Patients with non-primary colorectal cancer;\n2. Patients with liver metastasis or other organ metastasis;\n3. Patients without prehepatic CTC or whose prehepatic CTC were negative;\n4. People who are severely allergic to one or more of the drugs required in the test;\n5. Patients with severe underlying diseases of respiratory, circulatory, urinary and hematopoietic systems.","80 Years",{"count":221,"type":20},100,[23],"In this study, the Quintuple method was applied for early intervention of prehepatic CTC-positive bowel cancer patients without dominant liver metastasis, aiming to explore the blocking effect of the Quintuple method on the metachronous liver metastases of colorectal cancer. A one-arm randomized clinical trial was conducted, and the patients were grouped according to their treatment methods. The patients with metachronous liver metastases were used as the end point of the experiment to evaluate the blocking effect of quintuple therapy.",[225],"Preventive Effect of Quintuple Therapy on Metachronous Liver Metastases in Patients With Colorectal Cancer","2023-01-31",{"date":228,"type":37},"2023-02-09",{"date":230,"type":20},"2023-03-01",{"date":232,"type":20},"2026-09-01",{"name":43,"class":44},{"id":235,"slug":4,"hasResults":10,"nctId":236,"briefTitle":237,"officialTitle":238,"acronym":4,"eligibilityCriteria":239,"healthyVolunteers":10,"sex":53,"minAge":16,"maxAge":17,"enrollmentInfo":240,"targetDuration":4,"studyType":21,"phases":242,"briefSummary":243,"conditions":244,"keywords":247,"overallStatus":85,"whyStopped":4,"lastUpdateSubmitDate":249,"lastUpdatePostDateStruct":250,"startDateStruct":252,"completionDateStruct":254,"leadSponsor":256,"locationsCount":45},"100449477","NCT05132985","Neoadjuvant Icotinib With Chemotherapy for Epidermal Growth Factor Receptor(EGFR)-Mutated Resectable Lung Adenocarcinoma","Neoadjuvant Icotinib With Chemotherapy for Resectable Stage II-IIIB N2 EGFR Mutation-positive Lung Adenocarcinoma: A Phase II Study","Key Inclusion Criteria:\n\n* Written informed consent\n* Male or female, aged ≥18 years and ≤75 years\n* Histologically or cytologically documented lung adenocarcinoma with completely resectable disease (Stage II-IIIB N2, according to the 8th edition of the IASLC Staging Manual in Thoracic Oncology)\n* Complete surgical resection of the primary NSCLC must be deemed achievable, as assessed by an MDT evaluation\n* A tumor which harbors either Ex19del or L858R EGFR-TKI-sensitizing mutations, either alone\n* ECOG PS 0\u002F1 at enrollment, with no deterioration over the previous 2 weeks prior to baseline or day of first dosing\n* Adequate organ and marrow function as defined by:\n\n  * Hemoglobin: ≥9.0 g\u002FdL\n  * Absolute neutrophil count: ≥1.5 × 109\u002Fl\n  * Platelet count: ≥100 × 109\u002Fl\n  * Serum bilirubin: ≤1.5 ULN\n  * ALT and AST: ≤2.5 × ULN\n  * Creatinine clearance: ≥60 ml\u002Fmin\n* Life expectancy of 6 months prior to randomization\n\nExclusion Criteria:\n\n* Prior treatment with systemic anti-cancer treatment for NSCLC, EGFR-TKI treatment or pre-operative radiotherapy\n* EGFR-TKI-sensitizing mutations with T790M\n* Mixed small cell and non-small-cell lung cancer histology\n* T4 tumors infiltrating the aorta, esophagus and\u002For heart\n* Bulky N2 disease\n* Candidates for segmentectomies or wedge resections only\n* Medical history of ILD, drug-induced ILD, radiation pneumonitis which required steroid treatment or any evidence of clinically active ILD\n* Severe or uncontrolled systemic diseases\u002Factive infections, history of allogeneic organ transplantation, history of primary immunodeficiency, history of another primary malignancy",{"count":241,"type":20},45,[23],"Icotinib is a first-generation inhibitor of EGFR-tyrosine kinase inhibitor in patients with non-small-cell lung cancer (NSCLC). Here we will evaluate neoadjuvant Icotinib with chemotherapy prior to surgery, in patients with resectable stage II-IIIB N2 EGFR mutation-positive NSCLC. The primary endpoint is centrally assessed major pathological response at the time of resection. Secondary endpoints include pathological complete response, objective response rate, R0 resection rate at the time of resection, disease-free survival, and overall survival. Safety and tolerability will also be assessed.",[245,246],"NSCLC","EGF-R Positive Non-Small Cell Lung Cancer",[248],"NSCLC, EGFR, Icotinib","2021-11-28",{"date":251,"type":37},"2021-12-10",{"date":253,"type":20},"2022-01-01",{"date":255,"type":20},"2028-01-01",{"name":43,"class":44},""]